Top

Yinghong Wang, M.D., Ph.D., M.S.

Department of Gastroenterology Hepatology and Nutrition, Division of Internal Medicine

About Dr. Wang

Dr. Yinghong (Mimi) Wang is a Professor on Tenure Track in the Department of Gastroenterology, Hepatology & Nutrition. With a robust academic background comprising an M.D., Ph.D., and M.Sc., she brings extensive clinical experience from prestigious medical programs such as Johns Hopkins and Cleveland Clinic. Since joining MD Anderson in 2017, she has made significant contributions to the field of gastroenterology.

Dr. Wang's expertise lies in areas including Inflammatory Bowel Disease (IBD), fecal microbiota transplantation (FMT), and cancer immunotherapy-induced gastrointestinal toxicities. At MD Anderson, she has garnered recognition for her adept management of cancer immunotherapy-induced GI toxicities, establishing an IBD clinic and FMT service.

Taking a leading role in managing immunotherapy-related GI toxicities, Dr. Wang has developed updated management algorithms at institutional (https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/clinical-management/clin-management-immune-mediated-colitis-web-algorithm.pdf), national and international levels. Serving as the chair of the institutional immunotherapy toxicity working group since 2019, she has spearheaded numerous milestones, earning international acclaim as a leader in this field.

Dr. Wang and her team have achieved breakthroughs in treating immunotherapy-induced colitis with fecal transplant for refractory cases since 2017. Their pioneering work has been published in high-impact journals such as Nature Medicine and Science Translational Medicine, showcasing consistent high efficacy rates of 80-85% up to the year 2024. Currently three clinical trials in treating colitis are still ongoing. Two of these trials offer FMT to a larger patient population, aiming to maximize benefits while minimizing morbidities related to immunosuppressant use (NCT03819296, NCT04038619, NCT04407247).

Externally, Dr. Wang has served as a guideline panel member for immunotherapy-induced GI toxicity in several prominent oncology and gastroenterology societies in the US (ASCO, SITC, NCCN, AGA, ACG) and Europe (ESMO). She has also published a book titled "Managing Immunotherapy Related Organ Toxicities: A Practical Guide" as the editor (https://link.springer.com/book/10.1007/978-3-031-00241-0), with another handbook on Immunotherapy Related Organ Toxicities Cases set to be published in the fall of 2024. In addition, she has published over 150 scientific articles in peer-reviewed journals, book chapters and numerous national and international conference presentations.

Dr. Yinghong (Mimi) Wang's relentless dedication to advancing gastroenterology and improving patient care has earned her widespread recognition and acclaim in the medical community.

Patient education material for immunotherapy colitis management and clinical trials that are managed by Dr. Wang and her team:

https://www.mdanderson.org/patient-education/General-Internal-Medicine/Immunotherapy-Side-Effect-Colitis.pdf

https://www.mdanderson.org/patient-education/General-Internal-Medicine/Clinical-Trial-Treatments-for-Colitis-Related-to-Immune-Checkpoint-Inhibitors.pdf

https://www.mdanderson.org/patient-education/Gastrointestinal/Vowst-for-Fecal-Microbiota-Transplant.pdf

https://www.mdanderson.org/patient-education/Gastrointestinal/Rebyota-Fecal-Microbiota-Enema.pdf

https://www.mdanderson.org/patient-education/Bowel-Management/Fecal-Microbiota-Transplant-Through-Colonoscopy.pdf

For your education on the immunotherapy induced colitis overview and treatment, please clink on the following link for PPT slides. URL:https://mediaplayer.mdanderson.edu/video-full/247F62CA-742A-4E64-A40F-42570B25A0DE.

Dr. Wang speaks English and Mandarin Chinese fluently.

Meet Yinghong Wang, M.D., Ph.D.

Yinghong Wang, M.D., Ph.D., on cancer immunotherapy induced colitis

Fecal transplantation at MD Anderson

In the News

CGI anatomical drawing of electric blue small and large intestines superimposed over two open hands, held together, palm up

Fecal microbiota transplants: 10 questions, answered

With the help of immunotherapy, T cells can fight cancer.

Immunotherapy side effects: What to know

Mesothelioma survivor Christie Woodfin poses with Mediget Teshome, M.D.

Mesothelioma survivor: Why I support fecal transplant research

Present Title & Affiliation

Primary Appointment

Professor, Tenure Track, Department of Gastroenterology, Hepatology & Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Director of Oncology-GI Toxicity Program, Department of Gastroenterology Hepat & Nutr, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Associate Professor, Tenure Track, Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX

Director of Inflammatory Bowel Disorders, Department of Gastroenterology, Hepat,& Nutr, The University of Texas MD Anderson Cancer Center, Houston, TX

Chair of MD Anderson Institutional Immunotherapy Toxicity Working Group, Department of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Director of Fecal Microbiota Transplantation, Department of Gastroenterology, Hepat,& Nutr, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Tenure Track, Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Interests

Dr. Wang has a strong academic background (M.D., Ph.D., M.Sc.) and profound clinical experience from world renowned medical programs (Johns Hopkins, Cleveland Clinic). She has broad research collaboration network worldwide and holds >100 peer-reviewed publications and numerous international conference presentations. Her specialized areas include Inflammatory Bowel Disease (IBD), fecal microbiota transplantation (FMT), and cancer immunotherapy induced gastrointestinal toxicities.

Since joining MD Anderson in 12/2016, Dr. Wang has been recognized internationally for her expertise in managing cancer immunotherapy induced GI toxicities. She served as guideline panel member in four national and international oncology societies and gastroenterology society (ASCO, SITC, NCCN, ESMO, AGA), UPTODATE immunotherapy GI toxicity chapter, and also the chair of MD Anderson institutional immunotherapy toxicity working group. She contributed a new book entitled “Managing Immunotherapy Related Organ Toxicities, A Practical Guide” as the editor in 09/2022 (https://link.springer.com/book/10.1007/978-3-031-00241-0).

Dr. Wang and her team achieved multiple breakthroughs of successful treatment for immunotherapy induced colitis refractory to standard treatment and published her pioneer work on many prestigious journals such as NEJM, JCO, Nature Medicinewith great impact to this field. Dr. Wang and her team have launched three clinical trials in treating colitis and are actively enrolling patients (NCT03819296, NCT04038619, NCT04407247). Among them, two trials are offering FMT on a larger scale patient population to maximize the benefit and minimize the morbidities related to immunosuppressant use such as steroid.

For your education on the immunotherapy induced colitis overview and treatment, please clink on the following link for PPT slides. URL: https://mediaplayer.mdanderson.edu/video-full/247F62CA-742A-4E64-A40F-42570B25A0DE.

Dr. Wang speaks English and Mandarin Chinese fluently.

Clinical Interests

I specialize in inflammatory bowel disorders (inflammatory bowel disease, cancer therapy induced GI toxicities), and fecal microbiota transplantation for recurrent c diff and other GI disorders.

Education & Training

Degree-Granting Education

2005	Johns Hopkins University, Baltimore, Maryland, US, Cellular & Molecular Physiology, Ph.D
1999	The University of Calgary, Calgary, CA, Cardiovascular & Respiratory Sciences, M.Sc
1997	China Medical University, Shenyang, CN, Clinical Internship, MD

Postgraduate Training

2008-2011	Clinical Fellowship, Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio
2005-2008	Clinical Residency, Internal Medicine, Albany Medical Center, Albany, New York
1996-1997	Clinical Internship, China Medical University 2nd Affiliated Hospital, Shenyang

Board Certifications

2011	Gastroenterology
2008	Internal Medicine

Experience & Service

Academic Appointments

Associate Professor, Tenure Track, Department of Gastroenterology, Hepat,& Nutr, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2024

Associate Professor, Department of Gastroenterology, Hepat,& Nutr, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2021

Assistant Professor, Department of Gastroenterology, Hepat,& Nutr, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2019

Associate Staff, Cleveland Clinic Foundation, Cleveland, OH, 2011 - 2016

Administrative Appointments/Responsibilities

Director of Inflammatory Bowel Disorders, Department of Gastroenterology, Hepat,& Nutr, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present

Chair of MD Anderson Institutional Immunotherapy Toxicity Working Group, Department of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

Director of Fecal Microbiota Transplantation, Department of Gastroenterology, Hepat,& Nutr, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2021

Director of Medication Induced Colitis and Enteritis, Department of Gastroenterology, Hepat,& Nutr, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present

Other Appointments/Responsibilities

Editorial Board Member, South Texas Chapter of Crohn's and Colitis Foundation, Houston, TX, 2017 - Present

Honors & Awards

2023	Internal Medicine Division Faculty Research Excellence Award, University of Texas M D Anderson Cancer Center
2023	Elected Member, American Society of Clinical Investigation
2021	Distinguished Paper Award, University of Texas M.D. Anderson Cancer Center
2020	Immuno-Oncology Toxicity Research Award, The University of Texas MD Anderson Cancer Center
2019	Sabin Family fellowship Award, MD Anderson Cancer Center
2019	2nd Runner Up - Clinician Scientist Young Investigator Research Award, 5th Immuno-Oncology Young Investigator Forum
2019	President’s Recognition of Faculty Excellence Award in Research, MD Anderson Cancer Center
2018	Cyrus Research Awards, University of Texas MD Anderson Cancer Center
2018	Distinguished Paper Award for Basic Science, MD Anderson Cancer Center

Professional Memberships

American Society of Clinical Investigation

2023 - Present

ASCO

2021 - Present

American College of Gastroenterology (ACG)

2021 - Present

European Society of Medical Oncology (ESMO)

2021 - Present

Immune Checkpoint Inhibitor Toxicity Working Group, The University of Texas MD Anderson Cancer Center

2018 - Present

Society for Immunotherapy of Cancer

2018 - Present

South Texas Chapter of the Crohn’s & Colitis Foundation Medical Advisory Committee

2017 - Present

Journal of Inflammatory Bowel Disease

2017 - Present

National Comprehensive Cancer Network (NCCN)

2017 - Present

Society for Immunotherapy of Cancer (SITC)

2017 - Present

American Society of Clinical Oncology (ASCO)

2017 - Present

Harris County Medical Society

2016 - Present

Texas Society of Gastroenterology and Endoscopy

2016 - Present

Texas Gulf Coast Gastroenterological Society

2016 - Present

Crohn's and Colitis Foundation

2011 - Present

American College of Gastroenterology

2011 - Present

American Gastroenterology Association (AGA)

2010 - Present

Selected Publications

Peer-Reviewed Articles

Jayan A, Sukumar JS, Fangman B, Patel T, Raghavendra AS, Liu D, Pasyar S, Rauch R, Basen-Engquist K, Tripathy D, Wang Y, Khan SS, Barcenas CH. Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab. JCO Oncol Pract , 2024. PMID: 39388649.
Wang Y, Aleem A, Sarihan MC, Okhuysen PC, Roeland EJ, Schwartzberg L, Wang Y, Chaturvedi P. The impact of cancer-related diarrhea on changes in cancer therapy. Support Care Cancer 32(10):668, 2024. PMID: 39287693.
Urias Rivera AC, Machado AP, Shatila M, Triadafilopoulos G, McQuade JL, Altan M, Zhao D, Wang Y, Shafi MA. The Effect of Immune Checkpoint Inhibitor Therapy on Pre-Existing Gastroparesis and New Onset of Symptoms of Delayed Gastric Emptying. Cancers (Basel) 15(16):2658, 2024. e-Pub 2024. PMID: 39123385.
Harvey C, Nahar KJ, McKeown J, Lo SN, Farag S, Yousaf N, Young K, Tas L, Meerveld-Eggink A, Blank C, Thomas A, McQuade J, Schilling B, Johnson DB, Huertas RM, Arance A, Lee J, Zimmer L, Long GV, Carlino MS, Wang Y, Menzies AM. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J Immunother Cancer 12(1), 2024. e-Pub 2024. PMID: 38296594.
Shatila M, Eshaghi F, Thomas AR, Kuang AG, Shah JS, Zhao B, Naz S, Sun M, Fayle S, Jin J, Abudayyeh A, Sheshadri A, Palaskas NL, Franco-Vega MC, Gaeta MS, Thomas AS, Zhang HC, Wang Y. Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Cancers (Basel) 16(2), 2024. e-Pub 2024. PMID: 38254858.
Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang Y. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw:1-8. e-Pub 2024. PMID: 38190801.
Joerg V, Scheiner B, D Alessio A, Fulgenzi CAM, Schönlein M, Kocheise L, Lohse AW, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal YI, Chamseddine S, Phen S, Cheon J, Lee PC, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang YH, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal AG, Chon HJ, Pinato DJ, Schulze K, von Felden J. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study. Hepatol Commun 7(11), 2023. e-Pub 2023. PMID: 37889520.
Choucair K, Nebhan C, Cortellini A, Hentzen S, Wang Y, Liu C, Salama AK, Elliott A, Oberley MJ, Walker P, Giusti R, Filetti M, Ascierto PA, Vanella V, Galetta D, Catino A, Pizzutilo P, Genova C, Bersanelli M, Sebastiano, Buti, Saeed A, Mamdani H, Uprety D, El-Deiry WS, Beltran H, Nabhan C, Johnson DB, Claudia, Fulgenzi AM, Pinato DJ, Radford M, Liu SV, Kim C, Naqash AR, Saeed A. Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival. Cancers, 2023. e-Pub 2023. PMID: 37894419.
Machado AP, Shatila M, De Toni EN, Török H, Philpott J, Zhao D, Zhou Y, Varatharajalu K, Shafi MA, Zhang HC, Thomas AS, Wang Y. Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor–mediated Colitis. Journal of Cancer 14(14):2686 - 2693, 2023. e-Pub 2023. PMID: 37779873.
Gabriel S, Wang Y. Pouchitis After Immune Checkpoint Inhibitors. Annals of Internal Medicine Clinical Cases 2023 2(8), 2023. e-Pub 2023.
Halsey TM, Thomas AS, Hayase T, Ma W, Abu-Sbeih H, Sun B, Parra ER, Jiang ZD, DuPont HL, Sanchez C, El-Himri R, Brown A, Flores I, McDaniel L, Ortega Turrubiates M, Hensel M, Pham D, Watowich SS, Hayase E, Chang CC, Jenq RR, Wang Y. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. Sci Transl Med 15(700):eabq4006, 2023. e-Pub 2023. PMID: 37315113.
Badran YR, Zou F, Durbin SM, Dutra BE, Abu-Sbeih H, Thomas AS, Altan M, Thompson JA, Qiao W, Leet DE, Lai PY, Horick NK, Postow MA, Faleck DM, Wang Y, Dougan M. Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. J Immunother Cancer 11(6), 2023. e-Pub 2023. PMID: 37349130.
Abu-Sbeih H, Tang T, Ali FS, Ma W, Shatila M, Luo W, Tan D, Tang C, Richards DM, Ge PS, Thomas AS, Wang Y. Clinical Features and Management of Acute and Chronic Radiation-Induced Colitis and Proctopathy. Cancers(15):3160, 2023. e-Pub 2023. PMID: 37370770.
Kuang AG, Sperling G, Liang TZ, Lu Y, Tan D, Bollin K, Johnson DB, Manzano JM, Shatila M, Thomas AS, Thompson JA, Zhang HC, Wang Y. Sclerosing mesenteritis following immune checkpoint inhibitor therapy. J Cancer Res Clin Oncol. e-Pub 2023. PMID: 37195298.
Shatila M, Ma W, Cui Y, Naz S, S Thomas A, N De Toni E, Török HP, Khaled NB, Altan M, Schneider B, Wang Y. Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity. J Cancer Res Clin Oncol. e-Pub 2023. PMID: 37029815.
Dutra B, Garcia-Rodriguez V, Garcia R, Szafron D, Abraham F, Khurana S, Lockhart J, Amin R, Wang Y, Thomas A. Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors. Am J Clin Oncol 46(3):94-100, 2023. e-Pub 2023. PMID: 36735530.
Wang Y, Jenq RR, Wargo JA, Watowich SS. Microbiome influencers of checkpoint blockade-associated toxicity. J Exp Med 220(3), 2023. e-Pub 2023. PMID: 36622383.
Hanauer S, Wang Y, Shatila M. Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther 57(1):150-151, 2023. e-Pub 2023. PMID: 36468245.
Thomas AS, Abreo M, Sayed SA, Rao Manikonda SP, Eyada M, Issac A, Abraham F, Jacob JS, Wang Y, Yedururi S, Chari ST. Immune checkpoint Inhibitor-induced pancreatic injury Clinical and Radiological Profile and Response to Steroids. Gastro Hep Advances, 2023. e-Pub 2023.
Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol 14:1322818, 2023. e-Pub 2023. PMID: 38152395.
Kuang AG, Mohajir W, Panneerselvam K, McQuade JL, Oliva ICG, Khan MA, Zhang HC, Thomas AS, Wang Y. Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy. Ann Gastroenterol 36(1):45-53, 2023. e-Pub 2023. PMID: 36593813.
Grover S, MD, MPH, Wang Y, MD, PhD, Dougan M, MD, PhD. Immune Checkpoint Inhibitor Colitis, 2023. e-Pub 2023.
Liu C, Shatila M, Mathew A, Machado AP, Thomas A, Zhang HC, Thomas AS, Faleck D, Funchain P, Philpott J, Grivas P, Obeid M, Carbonnel F, Wang Y. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer. J Cancer 14(10):1913-1919, 2023. e-Pub 2023. PMID: 37476185.
Sperling G, Shatila M, Varatharajalu K, Lu Y, Altan M, Zhou Y, Zhao D, De Toni EN, Török H, Schneider BJ, Khan A, Thomas AS, Zhang HC, Wang Y. Pneumatosis intestinalis/coli in cancer patients who received immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2023. e-Pub 2023.
Thomas AR, Liu C, Tong YT, Tan D, Altan M, Siddiqui BA, Shatila M, Khan A, Thomas AS, Wang Y. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 36451045.
Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Mohamed YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Kudo M, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an international observational study. Liver Int. e-Pub 2022. PMID: 36577703.
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J, address: clinicalguidelines@esmoorg EGCE. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217-1238, 2022. e-Pub 2022. PMID: 36270461.
Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med 14(671):eabo3445, 2022. e-Pub 2022. PMID: 36383683.
Thomas AR, Eyada M, Kono M, Varatharajalu K, Lu Y, Xu G, Panneerselvam K, Shatila M, Altan M, Wang J, Thompson JA, Zhang HC, Khan MA, Raju GS, Thomas AS, Wang Y. Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 36242603.
Thomas AS, Abreo M, Sayed SA, Sireesha Yedururi YW, Chari ST. Autoimmune Pancreatitis Secondary to Immune Checkpoint Inhibitor Therapy (Type 3 AIP): Insights Into a New Disease From Serial Pancreatic Imaging. Gastroenterology. e-Pub 2022. PMID: 36220459.
Saji A, Chopra M, Jacob J, Altan M, Alhalabi O, Shah AY, Qiao W, Wang Y, Thomas A. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune‑mediated diarrhea and colitis. Journal of Cancer Research and Clinical Oncology, 2022. e-Pub 2022.
Mathew A, Shatila M, Lai Z, Tan D, Oliva ICG, Wang J, Alhalabi O, Zhang HC, Thomas A, Wang Y. Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 36163559.
Yu K, Mathew A, Abraham F, Amin R, Kono M, Overman M, Zhao D, Khan A, Khan MA, Thomas AS, Wang Y. Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes. Ann Gastroenterol 35(5):514-521, 2022. e-Pub 2022. PMID: 36061157.
Panneerselvam K, Szafron D, Amin RN, Wei D, Tan D, Altan M, Okhuysen PC, Shatila M, Raju GS, Thomas AS, Wang Y. Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors. Ann Gastroenterol 35(5):522-531, 2022. e-Pub 2022. PMID: 36061160.
Liu C, Amin R, Shatila M, Short N, Altan M, Shah A, Alhalabi O, Okhuysen P, Thomas AS, Wang Y. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 36030431.
Hollander B, Khurana S, Jacob JS, Altan M, Wang J, Zhao D, Varatharajalu K, Alasadi M, Thomas AS, Wang Y. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 35972690.
Abu-Sbeih H, Szafron D, Elkafrawy AA, Garcia-Rodriguez V, Ma W, Xu A, Khurana S, Numan L, Chen E, Goldstein R, Tsen A, Peng Y, Blum M, Kopetz ES, Ikoma N, Shatila M, Qiao W, Raju GS, Ross WA, Ge PS, Coronel E, Wang Y. Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. J Gastroenterol Hepatol. e-Pub 2022. PMID: 35730192.
Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40(5):509-523.e6, 2022. e-Pub 2022. PMID: 35537412.
Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. e-Pub 2022. PMID: 35481940.
Muhammed A, Fulgenzi CAM, Dharmapuri S, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Saeed A, Hildebrand H, Muzaffar M, Navaid M, Naqash AR, Gampa A, Ozbek U, Lin JY, Perone Y, Vincenzi B, Silletta M, Pillai A, Wang Y, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Di Tommaso L, Kudo M, Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Ang C, Pinato DJ. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers (Basel) 14(1), 2021. e-Pub 2021. PMID: 35008350.
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 39(36):JCO2101440, 2021. e-Pub 2021. PMID: 34724392.
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol 39(35):JCO2101992, 2021. e-Pub 2021. PMID: 34724386.
Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. JAMA Oncol. e-Pub 2021. PMID: 34734989.
Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 9(11), 2021. e-Pub 2021. PMID: 34789551.
Fessas P, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, Saeed A, Jun T, Dharmapuri S, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, Nishida N, Kudo M, Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Naqash AR, Sharon E, Cortellini A, Pinato DJ. Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. Liver Cancer 10(6):583-592, 2021. e-Pub 2021. PMID: 34950181.
Qian W, Ye Y, Zuo L, Song T, Xu Q, Wang Y, Qian J, Tian Y. Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis. Immunotherapy. e-Pub 2021. PMID: 34431319.
Jacob JS, Dutra BE, Garcia-Rodriguez V, Panneerselvam K, Abraham FO, Zou F, Ma W, Grivas P, Thompson JA, Altan M, Oliva ICG, Zhang HC, Thomas AS, Wang Y. Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. J Natl Compr Canc Netw. e-Pub 2021. PMID: 34348238.
Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
Ma W, Gong Z, Abu-Sbeih H, Peng Y, Peng F, Zou F, Charabaty A, Okhuysen PC, McQuade JL, Altan M, Zhang HC, Thomas AS, Wang Y. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. Am J Clin Oncol. e-Pub 2021. PMID: 34107499.
Khurana S, Abu-Sbeih H, Ma W, Qiao W, Foo WC, Richards DM, Thomas AS, Khan A, Zhang HC, Wang Y. Clinical Characteristics and Outcomes of Eosinophilic Colitis in Patients With Cancer. Am J Clin Oncol. e-Pub 2021. PMID: 34091476.
Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor (ICI) Colitis and Hepatitis: Expert Review. Gastroenterology 160(4):1384-1393, 2021. e-Pub 2021. PMID: 33080231.
Thomas AS, Ma W, Wang Y. Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors. N Engl J Med 384(6):581-583, 2021. e-Pub 2021. PMID: 33567198.
Panneerselvam K, Amin RN, Wei D, Tan D, Lum PJ, Zhang HC, Richards DM, Altan M, Grivas P, Thompson JA, Thomas AS, Wang Y. Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. J Natl Compr Canc Netw:1-9. e-Pub 2021. PMID: 34102607.
Zou F, Wang X, Glitza IC, McQuade JL, Wang J, Zhang HC, Thompson JA, Thomas AS, Wang Y. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 9(1), 2021. e-Pub 2021. PMID: 33436487.
Ali H, Khurana S, Ma W, Peng Y, Jiang ZD, DuPont H, Zhang HC, Thomas AS, Okhuysen P, Wang Y. Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients. J Cancer 12(21):6498-6506, 2021. e-Pub 2021. PMID: 34659541.
Zou F, Abu-Sbeih H, Ma W, Peng Y, Qiao W, Wang J, Shah AY, Glitza Oliva IC, Piha-Paul SA, Thompson JA, Zhang HC, Thomas AS, Wang Y. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. J Natl Compr Canc Netw:1-9. e-Pub 2020. PMID: 33316767.
Pinato DJ, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Fessas P, Nimkar N, Bettinger D, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Lozano-Kuehne J, Rimassa L, Ang C, Marron TU. Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33028690.
Ibraheim H, Baillie S, Samaan MA, Abu-Sbeih H, Wang Y, Talley NJ, P Jones M, Powell N. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther. e-Pub 2020. PMID: 32920854.
Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Rafeh Naqash A, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Benevento F, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Rimassa L, Ang C, Marron T, Pinato DJ. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 32868393.
Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32664319.
Thomas AS, Wang Y. Correspondence Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. e-Pub 2020. PMID: 32530825.
Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, Larkin J, Peters S, Thompson J, Obeid M. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32532839.
Abu-Sbeih H, Faleck DM, Dougan M, Wang Y. Reply to Y. Inagaki et al. J Clin Oncol:JCO2000295. e-Pub 2020. PMID: 32250720.
Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo WC, Richards DM, Halperin DM, Ge PS, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clin Colorectal Cancer. e-Pub 2020. PMID: 32284253.
Peng Y, Thomas AS, Wei D, Tan D, Wang Y. An Aggressive Approach Toward a Case of Refractory Ulcerative Colitis With Uncertain Etiology in the Context of Chronic Myeloid Leukemia. Inflamm Bowel Dis 26(4):e26-e27, 2020. e-Pub 2020. PMID: 32016290.
Abu-Sbeih H, Ali FS, Chen E, Mallepally N, Luo W, Lu Y, Foo WC, Qiao W, Okhuysen PC, Adachi JA, Hachem RY, Altan M, Jenq RR, Wang Y. Neutropenic Enterocolitis: Clinical Features and Outcomes. Dis Colon Rectum 63(3):381-388, 2020. e-Pub 2020. PMID: 31842164.
Chen E, Abu-Sbeih H, Thirumurthi S, Mallepally N, Khurana S, Wei D, Altan M, Morris VK, Tan D, Barcenas CH, Wang Y. Clinical characteristics of colitis induced by taxane-based chemotherapy. Ann Gastroenterol 33(1):59-67, 2020. e-Pub 2020. PMID: 31892799.
Abu-Sbeih H, Ali FS, Qiao W, Lum P, Shafi MA, Bresalier RS, Hawk E, Raju GS, Wang Y. Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia. J Cancer 11(11):3192-3198, 2020. e-Pub 2020. PMID: 32231724.
Abu-Sbeih H, Mallepally N, Goldstein R, Chen E, Tang T, Dike UK, Al-Asadi M, Westin S, Halperin D, Wang Y. Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy. J Cancer 11(11):3144-3150, 2020. e-Pub 2020. PMID: 32231718.
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol:JCO1901674. e-Pub 2019. PMID: 31800340.
Abu-Sbeih H, Ali FS, Tang T, Coronel E, Lee HJ, Pande M, Bresalier RS, Raju GS, Wang Y. Rate of colorectal neoplasia in patients with Hodgkin lymphoma. Colorectal Dis. e-Pub 2019. PMID: 31541529.
Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, Jenq RR, Wang Y. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer 7(1):242, 2019. e-Pub 2019. PMID: 31488205.
Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM, Ge PS, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Am J Clin Oncol. e-Pub 2019. PMID: 31478934.
Abu-Sbeih H, Ali FS, Ge PS, Barcenas CH, Lum P, Qiao W, Bresalier RS, Bhutani MS, Raju GS, Wang Y. Patients with breast cancer may be at higher risk of colorectal neoplasia. Ann Gastroenterol 32(4):400-406, 2019. e-Pub 2019. PMID: 31263363.
Lee JH, Emelogu I, Kukreja K, Ali FS, Nogueras-Gonzalez G, Lum P, Coronel E, Ross W, Raju GS, Lynch P, Thirumurthi S, Stroehlein J, Wang Y, You YN, Weston B. Safety and efficacy of metal stents for malignant colonic obstruction in patients treated with bevacizumab. Gastrointest Endosc 90(1):116-124, 2019. e-Pub 2019. PMID: 30797835.
Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol:JCO1900320. e-Pub 2019. PMID: 31163011.
Mallepally N, Abu-Sbeih H, Ahmed O, Chen E, Shafi MA, Neelapu SS, Wang Y. Clinical Features of Rituximab-associated Gastrointestinal Toxicities. Am J Clin Oncol 42(6):539-545, 2019. e-Pub 2019. PMID: 31136371.
Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer 7(1):118, 2019. e-Pub 2019. PMID: 31053161.
Abu-Sbeih H, Chen E, Ahmed O, Mallepally N, Lum P, Qiao W, Lee HJ, Bresalier R, Wang LS, Weston B, Raju GS, Wang Y. Patients with Non-Hodgkin's Lymphoma Are at Risk of Adenomatous Colon Polyps. Dig Dis Sci. e-Pub 2019. PMID: 31053975.
Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier RS, Richards DM, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol 13:1-8. e-Pub 2019. PMID: 31079556.
Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 7(1):93, 2019. e-Pub 2019. PMID: 30940209.
Tran CN, Abu-Sbeih H, Lu Y, Luo W, Wang Y. Vedolizumab achieved clinical and histological remission in a patient with lung cancer who had a steroid-refractory upper gastrointestinal injury due to nivolumab treatment. Journal of Immunotherapy and Precision Oncology 2(2):40-45, 2019. e-Pub 2019.
Zhang HC, Luo W, Wang Y. Acute Liver Injury in the Context of Immune Checkpoint Inhibitor-related Colitis Treated with Infliximab. J Immunother Cancer 7(1):47, 2019. e-Pub 2019. PMID: 30777137.
Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 7(1):31, 2019. e-Pub 2019. PMID: 30728076.
Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A, Wang Y. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother. e-Pub 2019. PMID: 30666357.
Abu-Sbeih H, Ali FS, Coronel E, Chen HC, Wang X, Lum P, Shuttlesworth G, Bhutani MS, Raju GS, Lee JH, Stroehlein JR, Ross WA, Wang Y. Safety of Endoscopy in cancer patients with Thrombocytopenia and Neutropenia. Gastrointest Endosc. e-Pub 2018. PMID: 30550744.
Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 6(1):142, 2018. e-Pub 2018. PMID: 30518410.
Cummings D, Cruise M, Lopez R, Roggenbuck D, Jairath V, Wang Y, Shen B, Rieder F. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch. Aliment Pharmacol Ther 48(11-12):1251-1259, 2018. e-Pub 2018. PMID: 30411391.
Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. e-Pub 2018. PMID: 30420754.
Abu-Sbeih H, Choi K, Tran CN, Wang X, Lum P, Shuttlesworth G, Stroehlein JR, Okhuysen PC, Wang Y. Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients. Eur J Gastroenterol Hepatol. e-Pub 2018. PMID: 30339561.
Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103, 2018. e-Pub 2018. PMID: 30305177.
Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 6(1):95, 2018. e-Pub 2018. PMID: 30253811.
Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, Gao J, Subudhi S, Stroehlein J, Wang Y. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?. Inflamm Bowel Dis. e-Pub 2018. PMID: 30169584.
Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, Zobniw C, Johnson DH, Samdani R, Lum P, Shuttlesworth G, Blechacz B, Bresalier R, Miller E, Thirumurthi S, Richards D, Raju G, Stroehlein J, Diab A. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflamm Bowel Dis 24(8):1695-1705, 2018. e-Pub 2018. PMID: 29718308.
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, Cancer Network NC. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714-1768, 2018. e-Pub 2018. PMID: 29442540.
Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 6(1):37, 2018. e-Pub 2018. PMID: 29747688.
Wang Y, Aggarwal P, Liu X, Lu H, Lian L, Wu X, Guo S, Aggarwal N, Lashner B, Shen B. Antiviral Treatment for Colonic Cytomegalovirus Infection in Ulcerative Colitis Patients Significantly Improved Their Surgery Free Survival. J Clin Gastroenterol 52(4):e27-e31, 2018. e-Pub 2018. PMID: 27875354.
Tian Y, Abu-Sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Colitis. Adv Exp Med Biol 995:151-157, 2018. e-Pub 2018. PMID: 30539510.
h A, Tang T, Ali F, Qiao W, Diab A, Wang Y. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes. J Immunother Precis Oncol 1(1):7-18, 2018. e-Pub 2018.
Tian Y, Abu-Sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Hepatitis. Adv Exp Med Biol 995:159-164, 2018. e-Pub 2018. PMID: 30539511.
Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS, Working Group SFIOCTM. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95, 2017. e-Pub 2017. PMID: 29162153.
Mehta PP, Kochhar G, Albeldawi M, Kirsh B, Rizk M, Putka B, John B, Wang Y, Breslaw N, Lopez R, Vargo JJ. Capnographic Monitoring in Routine EGD and Colonoscopy With Moderate Sedation: A Prospective, Randomized, Controlled Trial. Am J Gastroenterol 111(3):395-404, 2016. e-Pub 2016. PMID: 26902229.
Lai KK, Horvath B, Xie H, Wu X, Lewis BL, Pai RK, Plesec T, Patil DT, Gordon IO, Wang Y, Shen B, Goldblum JR, Liu X. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. Inflamm Bowel Dis 21(2):378-84, 2015. e-Pub 2015. PMID: 25569733.
Xu D, He CQ, He J, Yang H, Ma HM. Mitochondrial DNA sequence of the hybrid of Duroc (?) × [Landrace (?) × Yorshire (?)] pig. Mitochondrial DNA 26(5):682-3, 2015. e-Pub 2015. PMID: 24102607.
Xie H, Xiao SY, Pai R, Jiang W, Shadrach B, Carver P, Wang Y, Shen B, Zhou W, Liu X. Diagnostic utility of TP53 and cytokeratin 7 immunohistochemistry in idiopathic inflammatory bowel disease-associated neoplasia. Mod Pathol 27(2):303-13, 2014. e-Pub 2014. PMID: 23887291.
Wang Y, Atreja A, Wu X, Lashner BA, Brzezinski A, Shen B. Similar outcomes of IBD inpatients with Clostridium difficile infection detected by ELISA or PCR assay. Dig Dis Sci 58(8):2308-13, 2013. e-Pub 2013. PMID: 23525735.
Wang Y, Gong H, Lopez R, Lian L, Kiran RP, Soffer EE, Shen B. Correlation between serum serotonin and endoscopy inflammation scores in patients with ileal pouches. J Crohns Colitis 7(4):e133-42, 2013. e-Pub 2013. PMID: 22922006.
Wang Y, Bennett AE, Cai H, Lian L, Shen B. Evaluation of upper and lower gastrointestinal histology in patients with ileal pouches. J Gastrointest Surg 16(3):572-80, 2012. e-Pub 2012. PMID: 22052108.
Wang Y, Shen B. Clostridium difficile-associated diarrhea in Crohn's disease patients with ostomy. Inflamm Bowel Dis 16(1):1-2, 2010. e-Pub 2010. PMID: 19408324.
Cai H, Cebotaru V, Wang YH, Zhang XM, Cebotaru L, Guggino SE, Guggino WB. WNK4 kinase regulates surface expression of the human sodium chloride cotransporter in mammalian cells. Kidney Int 69(12):2162-70, 2006. e-Pub 2006. PMID: 16688122.
Wang Y, Cai H, Cebotaru L, Hryciw DH, Weinman EJ, Donowitz M, Guggino SE, Guggino WB. ClC-5: role in endocytosis in the proximal tubule. Am J Physiol Renal Physiol 289(4):F850-62, 2005. e-Pub 2005. PMID: 15942052.
Hara-Chikuma M, Wang Y, Guggino SE, Guggino WB, Verkman AS. Impaired acidification in early endosomes of ClC-5 deficient proximal tubule. Biochem Biophys Res Commun 329(3):941-6, 2005. e-Pub 2005. PMID: 15752747.
Hryciw DH, Wang Y, Devuyst O, Pollock CA, Poronnik P, Guggino WB. Cofilin interacts with ClC-5 and regulates albumin uptake in proximal tubule cell lines. J Biol Chem 278(41):40169-76, 2003. e-Pub 2003. PMID: 12904289.
Fewell JE, Smith FG, Ng VK, Wong VH, Wang Y. Postnatal age influences the ability of rats to autoresuscitate from hypoxic-induced apnea. Am J Physiol Regul Integr Comp Physiol 279(1):R39-46, 2000. e-Pub 2000. PMID: 10896862.
Msaouel P, Oromendia C, Siefker-radtke A, et al. Technology-enabled monitoring of patient-reported outcomes to detect and treat toxicities linked to immune checkpoint inhibitors.

Invited Articles

Gong Z, Wang Y. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. JCO Oncol Pract 16(8):OP2000002, 2020. e-Pub 2020. PMID: 32584703.
Abu-Sbeih H, Wang Y. Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. Inflamm Bowel Dis 26(5):662-668, 2020. e-Pub 2020. PMID: 31560045.
Abu-Sbeih H, Wang Y. Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis. Dig Dis Sci 65(3):797-799, 2020. e-Pub 2020. PMID: 32040664.
Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol 36(1):25-32, 2020. e-Pub 2020. PMID: 31609734.

Abstracts

Zarker AW, Wang Y. Combination vedolizumab and ustekinumab for refractory Crohn’s disease after immune checkpoint inhibitors. Eur J Gastroenterol Hepatol 37(2):240-241, 2024. e-Pub 2024. PMID: 39708337.
Sperling G, Wang Y. Diffuse metastatic melanoma in the GI lumen following immune checkpoint inhibitor colitis treatment. Case Rep Gastroenterol 2022 16(618-622), 2022. e-Pub 2022.
Amin R, Thomas AS, Wang Y. Fecal Transplant Sustained Colitis Remission on Immunotherapy Resumption. Annals of Internal Medicine Clinical Cases https://www.acpjournals.org/doi/10.7326/aimcc.2022.0490, 2022. e-Pub 2022.
Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 7(1):31, 2019. e-Pub 2019. PMID: 30728076.
Ali FS, Abu-Sbeih H, Hicklen R, Wang Y. Fearing the Unknown – The Fate of Inflammatory Bowel Disease after Fecal Microbiota Transplantation in Clostridium difficile Infection. American College of Gastroenterology Annual Conference, 2018. e-Pub 2018.
Tran C, Abu-Sbeih H, Luo W, y W. Vedolizumab achieved clinical and histological remission in a patient with lung cancer who had a steroid-refractory upper gastrointestinal injury due to nivolumab treatment. Society for Immunotherapy of Cancer, 2018. e-Pub 2018.
Abu-Sbeih H, Tang T, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. Society for Immunotherapy of Cancer, 2018. e-Pub 2018.
Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Faju GS, Stroehlein J, Diab A. Immune checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson Cancer Center. GIE 87(6):AB541-AB542, 2018. e-Pub 2018.
Abu-Sbeih H, Irshad QUA, Stroehlein JR, Okhuysen PC, Wand Y. Multiple Recurrent Clostridium Difficile Infection Is Associated with Treatment Failure and Prolonged Illness in Cancer Patients. GIE 87(6):AB398-AB399, 2018. e-Pub 2018.
Abi-Sbeih H, Ali FS, Hicklen R, Wang Y. Taming the Beast – The Safety and Efficacy of Fecal Microbiota Transplantation in Severe and Complicated Clostridium Difficile Infectino. American College of Gastroenterology Annual Conference, 2018. e-Pub 2018.
Choi K, Abu-Sbeih H, Samdani R, Gonzalez GN, Raju GS, Richards D, Gao J, Subudhi S, Stroehlein J, Wang Y. Features of Microscopic Colitis in Cancer Patients Receiving Immune Checkpoint Inhibitors. American College of Gastroenterology Annual Conference, 2018. e-Pub 2018.
Wang Y, DuPont H, Jian ZD, Jeng R, Zuazua R. Fecal microbiota transplant for immune-checkpoint inhibitor induced colitis in a 50 year old female with bladder cancer. Crohn’s and Colitis Congress meeting, 2018. e-Pub 2018.
Tang T, Abu-Sbeih H, Luo W, Samdani R, Lum P, Qiao W, Bresalier, Richards D, Wang Y. The Constellation of Upper Gastrointestinal Symptoms and associated Endoscopic and Histologic Features in Patients Receiving Immune Checkpoint Inhibitors. American College of Gastroenterology Annual Conference, 2018. e-Pub 2018.
Choi K, Samdani R, Wang Y. Systemic steroids in anti-PD1 induced collagenous colitis. Crohn’s and Colitis Congress meeting, 2018. e-Pub 2018.
Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A, Wang Y. The Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor Induced Colitis. American College of Gastroenterology Annual Conference, 2018. e-Pub 2018.
Zhang CH, Luo W, Wang Y. Acute Liver Injury in the Context of Immune Checkpoint Inhibitor-related Colitis Treated with Infliximab. Society for Immunotherapy of Cancer, 2018. e-Pub 2018.
Ali F, Samdani R, Wang Y. Short term endoscopic follow up on immune-checkpoint inhibitor induced colitis post treatment. Crohn’s and Colitis Congress meeting, 2018. e-Pub 2018.
Abu-Sbeih H, Ali FS, Gao J, Wang Y. The fate of immune–mediated diarrhea after the resumption of immune checkpoint inhibitor treatment. Society for Immunotherapy of Cancer, 2018. e-Pub 2018.
Abu-Sbeih H, Coronel E, Raju GS, Ross WA, Stroehlein JR, Lee JH, Bhutani M, Wang Y. Endoscopy Is Safe in Cancer Patients with Mild to Moderate Thrombocytopenia. DDW oral presentation 2018, GIE 87(6):AB92-AB93, 2018. e-Pub 2018.
Abu-Sbeih H, Shuttlesworth G, Samdani R, Zuazua R, Wang Y. Case series: immune-checkpoint inhibitors induced colitis treated with mesalamine. Crohn’s and Colitis Congress meeting, IBD 24 (suppl_1):S19-S19, 2018. e-Pub 2018.
Abu-Sbeih H, Ali FS, Bhuani MS, Raj GS, Jh L, Stroehlein JR, Ross WA, Wang Y. Endoscopy is safe in cancer patients with mild to moderate neutropenia. GIE 87(6):AB128, 2018. e-Pub 2018.
Abu-Sbeih H, Tang T, Richards DM, Westin JR, Neelapu SS Wang Y. Gastrointestinal symptoms observed after chimeric antigen receptor T–cell therapy. Society for Immunotherapy of Cancer, 2018. e-Pub 2018.
Choi K, Samdani R, Shuttlesworth G, Wang Y. Case series: immunotherapy-induced lymphocytic colitis. Crohn’s and Colitis Congress meeting, 2018. e-Pub 2018.
Abu-Sbeih H, Shuttlesworth G, Samdani R, Zuazua R, Wang Y. Immuno-checkpoint inhibitor induced colitis in a patient with lung cancer and colon metastasis treated with mesalamine: a case study. Crohn’s and Colitis Congress meeting 2018, IBD 24(suppl_1):S19-S19, 2018. e-Pub 2018.
Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of vedolizumab treatment in patients with immune checkpoint inhibitor induced diarrhea and colitis: A Multi-Center Study. American College of Gastroenterology Annual Conference oral presentation, 2018. e-Pub 2018.
Wang Y, Abu-Sbeih H, Choi K, Wiesnoski D, Helmink B, Gopalakrishnan V, DuPont H, Jiang ZD, Tetzlaff M, Wargo J, Jeng RR. Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis. Society for Immunotherapy of Cancer, 2018. e-Pub 2018.
Abu-Sbieh H, Tang T, Qiao W, Johnson D, Diab A, Wang Y. Outcomes of immune-checkpoint inhibitor induced organ toxicities. American Society of Clinical Oncology annual meeting (abstract number 10063) 2018, JCO 36, 2018 (suppl; abstr 10063), 2018. e-Pub 2018.
Abu-Sbieh H, Bhutani MS, Raju GS, Lee JH, Stroehlein JR, Ross WA, Wang Y. Predictors of overall survival in cancer patients who had endoscopic evaluation in the setting of neutropenia and thrombocytopenia. GIE 87(6):AB398-AB399, 2018. e-Pub 2018.
Abu-Sbeih H, Ali FS, Qiao W, Raju GS, Wang Y. Immune Checkpoint Inhibitor–Induced Colitis as a Predictor of Survival in Metastatic Melanoma. Society for Immunotherapy of Cancer, 2018. e-Pub 2018.
Wang Y, Abu-Sbeih H, Mao E, Ali N, Raju GS, Stroehlein J, Diab A. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. DDW poster 2018, GIE 87(6):AB541-AB542, 2018. e-Pub 2018.
Abu-Sbeih H, Ali FS, Hicklen R, Wang Y. Fecal Microbiota Transplantation for Clostridium difficile Infection in Immunocompromised Patients – Safe or Risky?. American College of Gastroenterology Annual Conference, 2018. e-Pub 2018.
Wang Y, Samdani R, Campbell M, Abraham S, Cotton I, Zuazua R. A Unique Case of Immunotherapy-Induced Colitis in a 50 Year Old Female with Bladder Cancer. American College of Gastroenterology annual meeting, 2017. e-Pub 2017.
Wang Y, Samdani R, Bhutani M, Zuazua R, Kebriaei P. A Unique Case of GI GVHD in a 37 year old Male with AML. American College of Gastroenterology annual meeting, 2017. e-Pub 2017.
Ali N, Wang Y, Zuazua R. Patients with immunotherapy induced colitis can benefit from non-immunosuppressive agents. American College of Gastroenterology annual meeting, 2017. e-Pub 2017.
Wang Y, Aggarwal P, Liu X, Lu H, Lian L, Wu X, Guo S, Aggarwal N, Lashner B, Shen B. Antiviral Treatment for Colonic Cytomegalovirus Infection in Ulcerative Colitis Patients Significantly Improved Their Surgery Free Survival. Ohio Gastroenterology Society, Columbus, OH, 2016. e-Pub 2016.
Wang Y, Shen B. Fecal Microbiota Transplantation in Refractory Clostridium Difficile Pouchitis. Crohn's and Colitis Foundation Association, Orlando, FL, 2015. e-Pub 2015.
Cummings D, Lopez R, Roggenbuck D, Wang Y, Shen B, Rieder F. Serum Anti-GP2 Antibody Isoforms 1 and 4 are Associated with Crohn's Disease of the Pouch in Patients with Ileal-Pouch Anal Anastomosis (IPAA). ACG, Honolulu, HI, 2015. e-Pub 2015.
Mehta PP, Kochhar G, Albeldawi M, Kirsh B, Rizk M, Putka B, John B, Wang Y, Breslaw N, Lopez R, Vargo JJ. Capnographic Monitoring Does Not Improve Detection of Hypoxemia in Colonoscopy with Moderate Sedation. A Randomized, Controlled Trial. ACG, Philadelphia, PA, 2014. e-Pub 2014.
Wang Y, Liu X, Lu H, Guo S, Lashner B, Shen B. Treatment for CMV Infection in UC Patients Significantly Decreased the Colectomy Rate. Crohn's and Colitis Foundation Association, Orlando, FL, 2014. e-Pub 2014.
Wang Y, Bennett AE, Lopez R, Shen B. Endoscopy Alone Is Sufficient for Pouch Disease Activity Monitoring and Prediction of Pouch Outcomes. ACG, San Diego, CA, 2013. e-Pub 2013.
Asava-aree C, Mu E, Patel V, Feng J, Lian L, Achkar JP, Lashner B, Shen B, Wang Y. CMV Treatment Does Not Improve Clinical Outcomes in IBD Inpatients with CMV Colitis. ACG, San Diego, CA, 2013. e-Pub 2013.
Wang F, Wang Y. Sclerosing Mesenteritis in a 50-Year-Old Male Successfully Treated with Tamoxifen. ACP, Northern Illinois Regional, Chicago, IL, 2013. e-Pub 2013.
Lai KK, Wang Y, Zie H, Shen B, Goldblum JR, Lewis BL, Liu X. Clinical Outcome after the Diagnosis of Indefinite for Dysplasia in Patients with Idiopathic Inflammatory Bowel Disease (IBD). United States & Canadian Academy of Pathology, Baltimore, MD, 2013. e-Pub 2013.
Xie H, X SY, Pai R, Lai K, Wang Y, Shen B, Liu X. Diagnostic Utility of p53 and Cytokeratin 7 Immunohistochemistry in Idiopathic Inflammatory Bowel Disease-Associated Neoplasia. United States & Canadian Academy of Pathology, Baltimore, MD, 2013. e-Pub 2013.
Mu E, Wu X, Atreja A, Feng J, Shen B, Lashner B, Wang Y. Analysis of Prevalence and Risk Factors for Active Disease of Crohn's Patients for Acute Exacerbation Symptoms. ACG, Las Vegas, NV, 2012. e-Pub 2012.
Wang F, Jiang W, Pai R, Downs-Kelly E, Wang Y. Helicobacter Heilmannii Infection in A 43-Year-Old Female Effectively Treated with the Standard Triple Therapy. ACP, Chicago, IL, 2012. e-Pub 2012.
Wang Y, Lee H, Shen B. Secondary Amyloidosis in a 70-Year-Old Patient with Crohn's Disease: Treatment with Oral Budesonide. ACG, Las Vegas, NV, 2012. e-Pub 2012.
Wang Y, Atreja A, Wu X, Lashner BA, Brzezinski A, Shen B. Inflammatory Bowel Disease Patients with Clostridium Difficile Infection by ELISA or PCR Assay. Digestive Disease Week, San Diego, CA, 2012. e-Pub 2012.
Wang Y, Ashish A, Xianrui W, Lashner BA, Brzezinski A, Shen B. Risk Factors and Outcome of Hospitalized Inflammatory Bowel Disease Patients with Clostridium Difficile Infection by ELISA or PCR Assay. Digestive Disease Week, 2012. e-Pub 2012.
Zhang C, Drazba J, Hatala D, Wang Y, Shen B. A Pilot Study: Development of A Novel Immunostaining Marker for Autoimmune Pouchitis. ACG, Washington, DC, 2011. e-Pub 2011.
Wang Y, Gong H, Lopez R, Soffer E, Shen B. Correlation between Serum Serotonin and Symptom and Endoscopy Inflammation Scores in Patients with Ileal Pouches. Digestive Disease Week, Chicago, IL, 2011. e-Pub 2011.
Wang Y, Bennett AE, Cai H, Shen B. Clinical Utility of Duodenal Histology in Diagnosis and Differential Diagnosis of Pouch Disorders. ACG, San Diego, CA, 2009. e-Pub 2009.
Wang Y, Cai H, Shen B. Clinical Utility of Mucosal Healing in Patients with Pouchitis. ACG, San Diego, CA, 2009. e-Pub 2009.
Wang Y, Ashley C. Leukemic Ascites: A Rare Cause of Acute Ascites. Am. J. Gastro, 2006. e-Pub 2006.

Book Chapters

Abu-Sbeih H, Wang Y. Gastrointestinal Tract Adverse Events. In: Adv Exp Med Biol, 247-253, 2020.
Abu-Sbeih H, Wang Y. Hepatobiliary Adverse Events. In: Adv Exp Med Biol, 271-276, 2020.
Tian Y, Abu-Sbeih H, Wang Y. Management for checkpoint inhibitor induced colitis and hepatitis. In: Immunotherapy. 2nd. Springer, 151-164, 2019.
Ali S, Abu-Sbeih H, Coronel E, Wang Y. Hepatobiliary disease in the cancer patient leading to critical illness. In: Oncologic Critical Care. Springer, 2019.
Wang Y, Guggino WB, Fong P. Anion Channels. In: Seldin and Giebishch's The Kidney: Physiology and Pathophysiology. 4th. Elsevier, 769-787, 2007.

Books (edited and written)

Wang Y. Managing immunotherapy related organ toxicity, a practice guide. Ed(s) 1st Edition. Springer International Publishing, 2022.

Less

Selected Presentations & Talks

Local Presentations

2023. Immunotherapy Induced GI Toxicity. Conference. Immunotherapy Induced GI Toxicity. Houston, TX, US.
2022. APRN Organization. Conference. APRN Organization. Houston, TX, US.
2022. ICI Scoring Project. Conference. ICI Scoring Project. Houston, TX, US.

Regional Presentations

2024. Immunotherapy Induced GI Toxicity. Conference. Immunotherapy Induced GI Toxicity.
2024. Immunotherapy Induced GI Toxicity. Conference. Immunotherapy Induced GI Toxicity. Cleveland, OH, US.
2024. Helicobacter pylori infection and response of gastric cancer to immunotherapy. 2. Effect of PD-1/ PD-L1 and statin combination therapy on gastrointestinal toxicity related to immune checkpoint inhibitors and on survival. Conference. 1.Helicobacter pylori infection and response of gastric cancer to immunotherapy. 2. Effect of PD-1/ PD-L1 and statin combination therapy on gastrointestinal toxicity related to immune checkpoint inhibitors and on survival. San Francisco, CA, US.
2023. Immunotherapy Induced GI Toxicity. Conference. Immunotherapy Induced GI Toxicity.
2023. ICI Colitis. Conference. ICI Colitis. Vancouver, CA.
2023. Colitis Cases. Conference. Colitis Cases.
2023. ICI Colitis. Conference. ICI Colitis. Coeur d'Alene, ID, US.
2023. ICI Colitis. Conference. ICI Colitis. Bloomington, MN, US.
2023. NCCN Tumor Board Planning Meeting. Conference. NCCN Tumor Board Planning Meeting.
2023. NCCN Guideline Panel Meeting. Conference. NCCN Guideline Panel Meeting.
2023. ICI Colitis Talk. Conference. ICI Colitis Talk.
2023. IBD. Conference. IBD.
2023. Case Discussion With Other Presenters. Conference. Case Discussion With Other Presenters. Orlando, FL, US.
2023. ICI, Cancer and Microbiome. Conference. ICI, Cancer and Microbiome. Malibu, CA, US.
2023. Grant Review. Conference. Grant Review.
2023. ICI Colitis and Pancreatitis. Conference. ICI Colitis and Pancreatitis.
2023. ICI Colitis. Conference. ICI Colitis.
2023. ICI Colitis. Conference. ICI Colitis.
2023. Scoring Project. Conference. Scoring Project.
2022. ICI Colitis. Conference. ICI Colitis.
2022. ICI Colitis Scoring Project. Conference. ICI Colitis Scoring Project. Charlotte, NC, US.
2022. ICI Colitis. Conference. ICI Colitis.
2022. FMT Trial for ICI Colitis. Conference. FMT Trial for ICI Colitis.
2022. IOTOX Practice. Conference. IOTOX Practice.
2022. ICI Colitis Cases. Conference. ICI Colitis Cases.
2022. FMT Trial. Conference. FMT Trial.
2022. ICI Colitis. Conference. ICI Colitis.
2022. ICI Colitis. Conference. ICI Colitis.
2022. ICI Colitis. Conference. ICI Colitis.

National Presentations

2024. Neurogastroenterology and motility, gastroparesis and small intestinal dysmotility or GI oncology. Conference. Neurogastroenterology and motility, gastroparesis and small intestinal dysmotility or GI oncology. Washington, DC, US.
2024. Worse Survival and Gastrointestinal Toxicity Outcomes among Checkpoint Inhibitor-treated Patients Receiving Proton Pump Inhibition. Conference. ASCO 2024. Chicago, Illinois, US.
2024. THE IMPACT OF PROTON-PUMP INHIBITOR USE ON THE INCIDENCE OF GASTROINTESTINAL TOXICITY TO CHECKPOINT INHIBITION. Conference. THE IMPACT OF PROTON-PUMP INHIBITOR USE ON THE INCIDENCE OF GASTROINTESTINAL TOXICITY TO CHECKPOINT INHIBITION. Washington, DC, US.
2024. 18F-FDG Uptake on Routine PET/CT for Cancer Surveillance to Predict The Incidence and Severity of Immune-Mediated Colitis. Conference. 18F-FDG Uptake on Routine PET/CT for Cancer Surveillance to Predict The Incidence and Severity of Immune-Mediated Colitis. Washington, DC, US.
2024. Immune Checkpoint Inhibitor Enterocolitis among Patients with History of Intraabdominal Surgical Intervention. Conference. Immune Checkpoint Inhibitor Enterocolitis among Patients with History of Intraabdominal Surgical Intervention. Washington, DC, US.
2024. Purastat® in hemostasis and prevention of gastrointestinal bleeding in patients with cancer. Conference. Purastat® in hemostasis and prevention of gastrointestinal bleeding in patients with cancer. Washington, DC, US.
2023. First-Line Treatment of Fecal Microbiota Transplantation for Immune-Mediated Colitis (oral presentation). Conference. First-Line Treatment of Fecal Microbiota Transplantation for Immune-Mediated Colitis (oral presentation). Chicago, IL, US.
2023. IMMUNE MEDIATED ADVERSE EVENT MANAGEMENT AT A TERTIARY CARE CANCER CENTER. Conference. IMMUNE MEDIATED ADVERSE EVENT MANAGEMENT AT A TERTIARY CARE CANCER CENTER. Chicago, IL, US.
2023. Fecal transplantation improved patients’ reported outcome after immune checkpoint inhibitor colitis (poster presentation). Conference. Fecal transplantation improved patients’ reported outcome after immune checkpoint inhibitor colitis (poster presentation). Chicago, IL, US.
2023. IMMUNE MEDIATED ADVERSE EVENT MANAGEMENT AT A TERTIARY CARE CANCER CENTER (poster presentation). Conference. IMMUNE MEDIATED ADVERSE EVENT MANAGEMENT AT A TERTIARY CARE CANCER CENTER (poster presentation). Chicago, IL, US.
2023. Comparative Gastrointestinal Toxicity Profile of Different ICI Regimens (poster presentation). Conference. Comparative Gastrointestinal Toxicity Profile of Different ICI Regimens (poster presentation). Chicago, IL, US.
2023. Randomized clinical trial of infliximab and vedolizumab in treating immune checkpoint inhibitor related colitis. (poster presentation). Conference. Randomized clinical trial of infliximab and vedolizumab in treating immune checkpoint inhibitor related colitis. (poster presentation). Chicago, IL, US.
2023. Randomized clinical trial of infliximab and vedolizumab in treating immune checkpoint inhibitor related colitis. Conference. Randomized clinical trial of infliximab and vedolizumab in treating immune checkpoint inhibitor related colitis. Chicago, IL, US.
2023. Comparative Gastrointestinal Toxicity Profile of Different ICI Regimen. Conference. Comparative Gastrointestinal Toxicity Profile of Different ICI Regimen. Chicago, IL, US.
2023. First-Line Treatment of Fecal Microbiota Transplantation for Immune-Mediated Colitis. Conference. ASCO. Chicago, IL, US.
2022. ICI Colitis Scoring Project. Conference. ACG. Charlotte, NC, US.
2022. ICI Colitis. Conference. Canada Oncology.
2022. NCCN Guideline. Conference. NCCN Guideline. Philadelphia, PA, US.
2022. ICI Colitis. Conference. Gordon Research Conference. Stonehill College, ME, US.
2022. ICI Colitis Case Presentation. Conference. DDW. San Diego, CA, US.
2022. Patricia and Ralph Giannella Lecture: Update on Immune Checkpoint Inhibitor-Induced Enterocolitis. Conference. DDW. San Diego, CA, US.
2022. ICI Colitis. Conference. ICI Colitis.
2022. Microbiome and IOTOX Initiative. Conference. Microbiome and IOTOX Initiative.
2022. ICI Colitis. Conference. ICI Colitis. Cleveland, OH, US.
2022. ICI Colitis. Conference. ICI Colitis. Las Vegas, NV, US.
2021. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with immune-mediated diarrhea and colitis. Conference. DDW, Poster, US.
2021. Clinical characteristics and outcomes of patients with positive celiac serology and cancer therapy exposure. Conference. DDW, Poster, US.
2021. Clinical profiles of asymptomatic immune check point inhibitor induced pancreatitis (ICI-PI). Conference. DDW, Poster, US.
2021. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in cancer patients: a multi-center study. Conference. DDW, Oral lecture, US.
2021. Incidence of Immune Checkpoint Inhibitor Related GI Toxicity in Patients with GI Luminal Malignancy and Outcomes after Treatment. Conference. DDW, Oral lecture, US.
2021. Characteristics, treatment, and outcomes of CMV infection in patients treated with immune checkpoint inhibitors. Conference. DDW, Oral lecture, US.
2021. Clostridioides Difficile infections in cancer patients on immune checkpoint inhibitors. Conference. DDW, Oral lecture, US.
2021. Immune checkpoint inhibitor resumption is associated with better long term outcome in cancer patients. Conference. DDW, Poster, US.
2021. Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma. Conference. ASCO, US.
2021. Maintenance therapy reduces recurrence of immune-mediated colitis after resumption of immunotherapy in cancer patients. Conference. DDW, Poster of distinction, US.
2021. Focused Expertise of IOTox GI Service Can Improve Quality of Clinical Care and Outcome of Immune Mediated Diarrhea/Colitis Among Inpatients: A Retrospective Review and Quality Improvement Project. Conference. ACG, Oral Presentation, US.
2021. Sustained Remission of Fecal Transplant-Treated Colitis After Immune Checkpoint Inhibitor Resumption. Conference. ACG, Presidential Poster Award, US.
2021. Establishing Upper GI Toxicity Remission with Vedolizumab Maintenance Therapy while Resuming Immune Checkpoint Inhibitor. Conference. ACG, Presidential Poster Award, US.
2021. Complicated diverticulitis after immune checkpoint inhibitor therapy. Conference. ACG, Presidential Poster Award, US.
2021. Diarrhea and Colitis Related to Immune Checkpoint Inhibitor and BRAF/MEK Inhibitor Therapy. Conference. ACG, Poster, US.
2021. Multi-organ failure after one dose of nivolumab in a patient with pre-existing ulcerative colitis. Conference. ACG, Poster, US.
2021. Microbiome alteration via Ffecal microbiota transplantation (FMT) is effective for immune checkpoint inhibitor (ICI) induced–colitis (IMC) refractory to immunosuppressive therapy. Conference. ACG, Poster, US.
2021. Characteristics and outcomes of cancer patients with venous thromboembolic events after treatment of immune checkpoint inhibitors. Conference. ACG, Poster, US.
2021. Budesonide as an Alternative Steroid Agent, in Combination With Adjunctive Agents, for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: A Case Study. Conference. ACG, Poster, US.
2021. Mesalamine and Cholestyramine for Immune-Mediated Diarrhea and Colitis. Conference. ACG, Poster, US.
2021. Clinical Characteristics and Outcomes of Tyrosine Kinase Inhibitor-Related Lower GI Toxicities. Conference. ACG, Poster, US.
2020. Comparative Study of Vedolizumab and Infliximab Treatment in Patients with Immune-mediated Diarrhea and Colitis (IMDC). Conference. ACG, Plenary oral presentation, US.
2020. EOSINOPHILIC COLITIS IN CANCER PATIENTS. Conference. EOSINOPHILIC COLITIS IN CANCER PATIENTS, US.
2020. Safety and Efficacy of Fecal Microbiota Transplantation in Cancer Patients with Recurrent Clostridium difficile Infection (rCDI). Conference. Safety and Efficacy of Fecal Microbiota Transplantation in Cancer Patients with Recurrent Clostridium difficile Infection (rCDI), US.
2020. Endoscopic treatment for gastrointestinal cancer bleeding. Conference. Endoscopic treatment for gastrointestinal cancer bleeding, US.
2020. Gastrointestinal infections in cancer patients with immune checkpoint inhibitor related colitis. Conference. Gastrointestinal infections in cancer patients with immune checkpoint inhibitor related colitis, US.
2020. Pembrolizumab-induced gastritis successfully treated with vedolizumab: A Case Study. Conference. ACG, US.
2020. Clinical Characteristics and Outcome of Oral Mucositis Associated with Immune Checkpoint Inhibitors in Patients with Cancer. Conference. ACG, Oral presentation, US.
2020. Clinicopathological features, treatment responses, and outcomes of immune checkpoint-inhibitor related esophagitis. Conference. ACG, US.
2020. Fecal microbiota transplant (FMT) for immune checkpoint inhibitor (ICI) induced–colitis (IMC) refractory to immunosuppressive therapy. Conference. ACG, US.
2020. Chronic Immune mediated Diarrhea and Colitis Is Associated with Better Cancer Outcomes. Conference. ACG, US.
2019. ANTI-ANGIOGENESIS CANCER THERAPY-RELATED GASTROINTESTINAL INJURY CAN LEAD TO SERIOUS ADVERSE CONSEQUENCES IN A SMALL PROPORTION OF PATIENTS. Conference. AGA. San Diego, CA, US.
2019. IMPORTANCE OF ENDOSCOPIC AND HISTOLOGICAL EVALUATION IN THE MANAGEMENT OF IMMUNE CHECKPOINT INHIBITOR-INDUCED COLITIS. Conference. AGA. San Diego, CA, US.
2019. ARE PATIENTS WITH NON-COLORECTAL CANCER AT INCREASED RISK OF COLONIC ADENOMA?. Conference. AGA. San Diego, CA, US.
2019. CLINICAL CHARACTERISTICS AND OUTCOMES OF IMMUNE CHECKPOINT INHIBITOR-INDUCED PANCERATIC INJURY. Conference. AGA. San Diego, CA, US.
2019. FECAL MICROBIOTA TRANSPLANTATION FOR IMMUNE CHECKPOINT INHIBITOR INDUCED-COLITIS RESISTANT TO IMMUNOSUPPRESSIVE THERAPY. Conference. AGA. San Diego, CA, US.
2019. CLINICAL FEATURES OF RITUXIMAB-INDUCED GASTROINTESTINAL TOXICITIES. Conference. AGA. San Diego, CA, US.
2019. PLATINUM BASED THERAPY IN PATIENTS WITH CANCER LEADING TO GASTROINTESTINAL ADVERSE EVENTS. Conference. AGA. San Diego, CA, US.
2019. CLINICAL CHARACTERISTICS OF TAXANE-BASED CHEMOTHERAPY-INDUCED COLITIS. Conference. AGA. San Diego, CA, US.
2019. NEUTROPENIC COLITIS - CLINICAL FEATURES, TREATMENT AND OUTCOMES. Conference. AGA. San Diego, CA, US.
2019. CAN CHOLECYSTITIS BE AN ADVERSE EVENT FROM IMMUNE CHECKPOINT INHIBITOR TREATMENT?. Conference. AGA. San Diego, CA, US.
2019. GASTROINESTINAL SYMPTOMS OBSERVED AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY. Conference. AGA. San Diego, CA, US.
2019. EARLY INTRODUCTION OF NON-STEROIDAL IMMUNOSUPPRESSIVE THERAPY ASSOCIATED WITH FAVORABLE CLINICAL OUTCOMES IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-INDUCED COLITIS. Conference. AGA. San Diego, CA, US.
2019. Are patients with non–colorectal cancer at increased risk of colonic adenoma?. Conference. Are patients with non–colorectal cancer at increased risk of colonic adenoma?. San Diego, CA, US.
2019. Risk of colon adenoma in patients with breast cancer. Conference. Risk of colon adenoma in patients with breast cancer. Chicago, IL, US.
2019. Early introduction of non-steroidal immunosuppressive therapy for immune checkpoint inhibitor–induced colitis associated with favorable clinical outcomes. Conference. Early introduction of non-steroidal immunosuppressive therapy for immune checkpoint inhibitor–induced colitis associated with favorable clinical outcomes, US.
2019. Immune–mediated colitis after resumption of immune checkpoint inhibitor therapy. Conference. Immune–mediated colitis after resumption of immune checkpoint inhibitor therapy. Chicago, IL, US.
2019. Risk of colon adenoma in patients with breast cancer. Conference. ASCO, US.
2019. Outcomes after early initiation of nonsteroidal immunosuppressive therapy in patients with immune checkpoint inhibitor–induced colitis. Conference. Outcomes after early initiation of nonsteroidal immunosuppressive therapy in patients with immune checkpoint inhibitor–induced colitis. Chicago, IL, US.
2019. Clinical features of platinum based cancer therapy related gastrointestinal toxicities. Conference. Clinical features of platinum based cancer therapy related gastrointestinal toxicities, US.
2019. VEGF-related gastrointestinal injury can lead to serious adverse consequences in a small proportion of patients. Conference. VEGF-related gastrointestinal injury can lead to serious adverse consequences in a small proportion of patients, US.
2018. Endoscopy Is Safe in Cancer Patients with Mild to Moderate Thrombocytopenia. Conference. DDW oral presentation, US.
2018. Predictors of overall survival in cancer patients who had endoscopic evaluation in the setting of neutropenia and thrombocytopenia. Conference. DDW, US.
2018. Multiple Recurrent Clostridium Difficile Infection Is Associated with Treatment Failure and Prolonged Illness in Cancer Patients. Conference. DDW, US.
2018. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Conference. DDW, US.
2018. Immune checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson Cancer Center. Conference. DDW, US.
2018. Systemic steroids in anti-PD1 induced collagenous colitis. Conference. Crohn’s and Colitis Congress Meeting, US.
2018. Case series: immunotherapy-induced lymphocytic colitis. Conference. Crohn’s and Colitis Congress meeting, US.
2018. Case series: immune-checkpoint inhibitors induced colitis treated with mesalamine. Conference. Crohn’s and Colitis Congress meeting, US.
2018. Immuno-checkpoint inhibitor induced colitis in a patient with lung cancer and colon metastasis treated with mesalamine: a case study. Conference. Crohn’s and Colitis Congress meeting, US.
2018. Short term endoscopic follow up on immune-checkpoint inhibitor induced colitis post treatment. Conference. Crohn’s and Colitis Congress meeting, US.
2018. Fecal microbiota transplant for immune-checkpoint inhibitor induced colitis in a 50 year old female with bladder cancer. Conference. Crohn’s and Colitis Congress meeting, US.
2018. Role of infliximab in the management of immune-checkpoint inhbitors-mediated colitis. Conference. Crohn’s and Colitis Congress meeting, US.
2018. Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis. Conference. Society for Immunotherapy of Cancer, US.
2018. Gastrointestinal symptoms observed after chimeric antigen receptor T–cell therapy. Conference. Society for Immunotherapy of Cancer, US.
2018. Fearing the Unknown – The Fate of Inflammatory Bowel Disease after Fecal Microbiota Transplantation in Clostridium difficile Infection. Conference. ACG, US.
2018. Fecal Microbiota Transplantation for Clostridium difficile Infection in Immunocompromised Patients – Safe or Risky?. Conference. ACG, US.
2018. Taming the Beast – The Safety and Efficacy of Fecal Microbiota Transplantation in Severe and Complicated Clostridium Difficile Infectino. Conference. ACG, US.
2018. Features of Microscopic Colitis in Cancer Patients Receiving Immune Checkpoint Inhibitors. Conference. ACG, US.
2018. Outcomes of vedolizumab treatment in patients with immune checkpoint inhibitor induced diarrhea and colitis: A Multi-Center Study. Conference. ACG oral presentation, US.
2018. The Constellation of Upper Gastrointestinal Symptoms and associated Endoscopic and Histologic Features in Patients Receiving Immune Checkpoint Inhibitors. Conference. ACG, US.
2018. The Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor Induced Colitis. Conference. ACG, US.
2018. Immune Checkpoint Inhibitor–Induced Colitis as a Predictor of Survival in Metastatic Melanoma. Conference. Society for Immunotherapy of Cancer, US.
2018. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. Conference. Society for Immunotherapy of Cancer, US.
2018. The fate of immune–mediated diarrhea after the resumption of immune checkpoint inhibitor treatment. Conference. Society for Immunotherapy of Cancer, US.
2018. Acute Liver Injury in the Context of Immune Checkpoint Inhibitor-related Colitis Treated with Infliximab. Conference. Society for Immunotherapy of Cancer, US.
2018. Vedolizumab achieved clinical and histological remission in a patient with lung cancer who had a steroid-refractory upper gastrointestinal injury due to nivolumab treatment. Conference. Society for Immunotherapy of Cancer, US.
2018. Endoscopy is safe in cancer patients with mild to moderate neutropenia. Conference. DDW oral presentation, US.
2017. A Unique Case of Immunotherapy-Induced Colitis in a 50 Year Old Female with Bladder Cancer. Conference. ACG, US.
2017. Patients with immunotherapy induced colitis can benefit from non-immunosuppressive agents. Conference. ACG, US.
2017. A Unique Case of GI GVHD in a 37 year old Male with AML. Conference. ACG, US.
2016. Antiviral Treatment for Colonic Cytomegalovirus Infection in Ulcerative Colitis Patients Significantly Improved Their Surgery Free Survival. Conference. Ohio Gastroenterology Society Annual Meeting, US.
2015. Fecal Microbiota Transplantation in Refractory Clostridium Difficile Pouchitis. Conference. Crohn’s and Colitis Foundation Association annual meeting, US.
2015. Serum Anti-GP2 Antibody Isoforms 1 and 4 are Associated with Crohn’s Disease of the Pouch in Patients with Ileal-Pouch Anal Anastomosis (IPAA). Conference. ACG, US.
2014. Capnographic Monitoring Does Not Improve Detection of Hypoxemia in Colonoscopy with Moderate Sedation. A Randomized, Controlled Trial. Conference. ACG, US.
2014. Treatment for CMV Infection in UC Patients Significantly Decreased the Colectomy Rate. Conference. Crohn’s and Colitis Foundation Association annual meeting 2014, US.
2013. Endoscopy Alone Is Sufficient for Pouch Disease Activity Monitoring and Prediction of Pouch Outcomes. Conference. ACG, US.
2013. CMV Treatment Does Not Improve Clinical Outcomes in IBD Inpatients with CMV Colitis. Conference. ACG, US.
2013. Clinical Outcome after the Diagnosis of Indefinite for Dysplasia in Patients with Idiopathic Inflammatory Bowel Disease (IBD). Conference. United States & Canadian Academy of Pathology Annual Meeting, US.
2012. Risk Factors and Outcome of Hospitalized Inflammatory Bowel Disease Patients with Clostridium Difficile Infection by ELISA or PCR Assay. Conference. DDW, US.
2012. Analysis of Prevalence and Risk Factors for Active Disease of Crohn’s Patients for Acute Exacerbation Symptoms. Conference. ACG, US.
2012. Systemic Secondary Amyloidosis in a 70-Year-Old Patient with Crohn’s Disease: Treatment with Oral Budesonide. Conference. ACG, US.
2011. Correlation between Serum Serotonin and Symptom and Endoscopy Inflammation Scores in Patients with Ileal Pouches. Conference. DDW, US.
2011. A Pilot Study: Development of A Novel Immunostaining Marker for Autoimmune Pouchitis. Conference. ACG, US.
2009. Clinical Utility of Mucosal Healing in Patients with Pouchitis. Conference. ACG, US.
2009. Clinical Utility of Duodenal Histology in Diagnosis and Differential Diagnosis of Pouch Disorders. Conference. ACG, US.
2006. Leukemic Ascites: A Rare Cause of Acute Ascites. Conference. Am. J. Gastro, US.
2006. Down-Regulation of Surface Expression of Sodium Chloride Cotransporter (NCC) by WNK4 Kinase Is Partially Due to Its Enhanced Degradation through A Lysosomal Pathway. Conference. J. Am. Soc. Nephrol, US.
2004. Role of Chloride Transport by CLC-5 on Endosomes in Endocytosis. Conference. J. Am. Soc. Nephrol, US.
2003. Defective Processing of CLC-5 Mutants. Conference. J. Am. Soc. Nephrol, US.

International Presentations

2023. Gastrointestinal Toxicities of Proteasome Inhibitor Therapy. Conference. Gastrointestinal Toxicities of Proteasome Inhibitor Therapy. Vancouver, CA.
2023. An Unusual Presentation of GI complication related to Immune Checkpoint Inhibitor Therapy. Conference. An Unusual Presentation of GI complication related to Immune Checkpoint Inhibitor Therapy. Vancouver, CA.
2023. An Unusual Presentation of GI complication related to Immune Checkpoint Inhibitor Therapy. Conference. An Unusual Presentation of GI complication related to Immune Checkpoint Inhibitor Therapy. Vancouver, CA.
2023. Effect of PD-1/ PD-L1 and Statin Combination Therapy on Gastrointestinal Toxicity Related to Immune Checkpoint Inhibitors and on Survival. Conference. Effect of PD-1/ PD-L1 and Statin Combination Therapy on Gastrointestinal Toxicity Related to Immune Checkpoint Inhibitors and on Survival. Vancouver, CA.
2023. Fecal Transplantation Improved Patients' Reported Outcome After Immune Checkpoint Inhibitor Colitis. Conference. Fecal Transplantation Improved Patients' Reported Outcome After Immune Checkpoint Inhibitor Colitis. Vancouver, CA.
2023. Frontline Fecal Transplantation for Immune Checkpoint Inhibitor Colitis. Conference. Frontline Fecal Transplantation for Immune Checkpoint Inhibitor Colitis. Vancouver, CA.
2023. Gastrointestinal Adverse Events Following Brentuximab Vedotin and Polatuzumab Vedotin Therapy. Conference. Gastrointestinal Adverse Events Following Brentuximab Vedotin and Polatuzumab Vedotin Therapy. Vancouver, CA.
2023. Helicobacter Pylori Seropositivity Is Associated With Worse Outcomes Among Patients on Immunotherapy for Gastric Cancer. Conference. Helicobacter Pylori Seropositivity Is Associated With Worse Outcomes Among Patients on Immunotherapy for Gastric Cancer. Vancouver, CA.
2023. Immune Checkpoint Inhibitor-Associated Gastrointestinal Adverse Events in Patients With Colorectal Cancer. Conference. Immune Checkpoint Inhibitor-Associated Gastrointestinal Adverse Events in Patients With Colorectal Cancer. Vancouver, CA.
2023. Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor Related Colitis in Patients with Cancer. Conference. Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor Related Colitis in Patients with Cancer. Vancouver, CA.
2023. Practice Changes in Management of Gastrointestinal Immune-Related Adverse Events at a Tertiary Care Cancer Center. Conference. Practice Changes in Management of Gastrointestinal Immune-Related Adverse Events at a Tertiary Care Cancer Center. Vancouver, CA.
2023. Rectal Ulcer and Fistula Development in a Cancer Patient on Immune Checkpoint Inhibitor Immunotherapy: A Case Report. Conference. Rectal Ulcer and Fistula Development in a Cancer Patient on Immune Checkpoint Inhibitor Immunotherapy: A Case Report. Vancouver, CA.
2023. Similar Features of PET Scan in Gastrointestinal Tract Related to Metformin and Immune Related Enterocolitis. Conference. Similar Features of PET Scan in Gastrointestinal Tract Related to Metformin and Immune Related Enterocolitis. Vancouver, CA.
2023. The Interplay Between Immunocompromise and Immunotherapy Affects the Risk of Inflammatory Adverse Events. Conference. The Interplay Between Immunocompromise and Immunotherapy Affects the Risk of Inflammatory Adverse Events. Vancouver, CA.
2023. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Conference. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Vancouver, CA.
2023. Therapeutic Drug Monitoring of Vedolizumab in Management of Immune Checkpoint Inhibitor-Mediated Colitis. Conference. Therapeutic Drug Monitoring of Vedolizumab in Management of Immune Checkpoint Inhibitor-Mediated Colitis. Vancouver, CA.
2022. ICI Colitis. Conference. United European Gastroenterology Week. Vienna, AT.
2018. Outcomes of immune-checkpoint inhibitor induced organ toxicities. Conference. American Society of Clinical Oncology, US.

Formal Peers

2024. Immunotherapy Induced GI Toxicity. Invited. Immunotherapy Induced GI Toxicity, US.
2024. Immunotherapy Induced GI Toxicity. Invited. Immunotherapy Induced GI Toxicity, US.
2023. Immunotherapy Induced GI Toxicity. Invited. Immunotherapy Induced GI Toxicity, CN.
2023. Immunotherapy Induced GI Toxicity. Invited. Immunotherapy Induced GI Toxicity, CN.
2021. Immunotherapy Induced GI Toxicity. Invited. Immunotherapy Induced GI Toxicity, CA.
2020. Immunotherapy Induced GI Toxicity. Invited. Immunotherapy Induced GI Toxicity, US.
2019. Immunotherapy Induced GI Toxicity. Invited. Immunotherapy Induced GI Toxicity, US.
2018. Immunotherapy Induced GI Toxicity. Invited. Immunotherapy Induced GI Toxicity, US.
2018. Immunotherapy Induced GI Toxicity. Invited. Immunotherapy Induced GI Toxicity, CN.

Less

Grant & Contract Support

Date:	2022 - 2025
Title:	Management of Immunotherapy GI Toxicity
Funding Source:	Cyrus Research Award
Role:	PI

Date:	2021 - 2024
Title:	Faculty Start-Up Fund
Funding Source:	University of Texas, MD Anderson Cancer Center
Role:	PI

Date:	2021 - 2024
Title:	Fecal microbiota transplantation to manage immune-mediated colitis
Funding Source:	Gateway Research Award
Role:	PI

Date:	2020 - 2024
Title:	Treatment of immune checkpoint inhibitor-related colitis with infliximab or vedolizumab: A Randomized Trial
Funding Source:	University of Texas MD Anderson Cancer Center Immuno-Oncology Toxicity Program, Division of Internal Medicine
Role:	PI

Date:	2020 - 2024
Title:	GHN Stool Bank
Funding Source:	University of Texas MD Anderson Cancer Center Division of Internal Medicine and Department of Gastroenterology, Hepatology and Nutritio
Role:	PI

Date:	2020 - 2024
Title:	Modulating the gut-tumor microbial axis to reverse pancreatic cancer immunosuppression
Funding Source:	Cancer Prevention Research Institute of Texas
Role:	Co-PI

Date:	2020 - 2022
Title:	Fecal microbiota treatment for immune checkpoint inhibitor mediated colitis
Funding Source:	HESI/THRIVE
Role:	PI

Date:	2019 - 2023
Title:	Modulating the gut-tumor microbial axis to reverse pancreatic cancer immunosuppression
Funding Source:	V Foundation
Role:	Collaborator

Date:	2019 - Present
Title:	Fecal microbiota transplantation to manage immune-mediated colitis
Funding Source:	Houston Cancer Fighter
Role:	Co-PI

Date:	2019 - 2021
Title:	Usage of Fecal Microbiota Transplantation (FMT) for Immunomodulation in Cancer
Funding Source:	University of Texas, MD Anderson Cancer Center (Wang) Moonshot Operations Program
Role:	PI

Date:	2019 - 2024
Title:	Targeting STAT3 to Prevent Colorectal Cancer (CRC) in Hereditary Syndromes and Inflammatory Bowel Disease
Funding Source:	NIH/NCI
Role:	PI Project 2

Date:	2019 - 2021
Title:	Investigational fecal transplantation for immune-checkpoint inhibitor induced-colitis in patients with cancer
Funding Source:	Adopt-A-Scientist
Role:	PI

Date:	2019 - 2021
Title:	Fecal microbiota transplantation: The first line treatment of immune checkpoint inhibitor– related colitis
Funding Source:	Sabin Family Fellowship Program
Role:	Postdoctoral Fellow

Date:	2019 - Present
Title:	Fecal Microbiota Transplantation to Manage Immune-Mediated Colitis
Funding Source:	Houston Cancer Fighter
Role:	PI
ID:	2018-0383

Title:	Initiated Clinical Trial on SOR101 Treatment for ICI Colitis
Funding Source:	Sorriso Pharma
Role:	Investigator

Title:	Initiated Clinical Trial on PuraStat in Combination with Fecal Microbiota Transplantation in Treatment of ICI Colitis
Funding Source:	3-D Matrix Biotechnology
Role:	Investigator

Title:	Investigator Initiated Clinical Trial on Ustekinumab Treatment for ICI Colitis
Funding Source:	Janssen Pharma
Role:	Investigator

Title:	Fecal microbiota transplantation: The first line treatment of immune checkpoint inhibitor– related colitis
Funding Source:	Sabin Family Fellowship Program
Role:	Collaborator

Title:	Randomized trial of infliximab and vedolizumab in treating immune checkpoint inhibitor induced colitis
Funding Source:	Sabin Family Fellowship Program
Role:	Collaborator

CV information above last modified April 18, 2025

Yinghong Wang, M.D., Ph.D., M.S.

About Dr. Wang

In the News

Fecal microbiota transplants: 10 questions, answered

Immunotherapy side effects: What to know

Mesothelioma survivor: Why I support fecal transplant research

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Gastroenterology, Hepatology & Nutrition Department

Gastrointestinal Center

Colorectal Center

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer